Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 1, 1996, Pages 89-96

  Sironi, Luigi ^b   Mussoni, Luciana ^b   Prati, Livia ^b   Baldassarre, Damiano ^a   Camera, Marina ^b   Banfi, Cristina ^b   Tremoli, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

gene expression; HepG2; insulin; plasminogen activator inhibitor type 1; VLDL

Indexed keywords

LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; CELL STRAIN HEPG2; GENE EXPRESSION; GENETIC TRANSCRIPTION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RNA TRANSCRIPTION; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030059836     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.1.89     Document Type: Article

References (47)

1. Bachmann F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen HR, Arnout J, eds. Thrombosis and Haemostasis. Leuven, Belgium: Leuven University Press; 1987:227-265.
2. Jansen JWCM, Reinders JH. Fibrinolysis: system and processes. Coron Artery Dis. 1992;3:425-434.
3. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381-387.
4. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 1993;70:138-141.
5. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor 1. Metabolism. 1990;39:1044-1048.
6. Juhan-Vague I, Roui C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost. 1989;61:370-373.
7. Scelles V, Raccah D, Alessi MC, Vialle JM, Juhan-Vague I, Vague P. Plasminogen Activator Inhibitor 1 and insulin levels in various insulin resistance states. Diabete Metab. 1992;18:38-42.
8. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
9. Austin MA. Plasma triglyceride as a risk factor for coronary heart disease: the epidemiological evidence beyond. Am J Epidemiol. 1989;129:249-259.
10. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992;70:3H-9H.
11. Assmann G, Shulte H. Role of triglycerides in coronary artery disease: lessons from the prospective cardiovascular Munster study. Am J Cardiol. 1992;70:10H-13H.
12. Andersen P, Arnesen H, Hjerman I. Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand. 1981;209:199-202.
13. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol. 1987;9:263-268.
14. Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 1988;59:535-541.
15. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 1991;12:19-27.
16. Hamsten A, Wiman B, deFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
17. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis. 1991;5:197-206.
18. Stiko-Rahm A, Wiman B. Hamsten A. Nilsson J. Secretion of plasminogen activator inhibitor I from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 1990;10:1067-1073.
19. Mussoni L, Maderna P, Camera M, Bernini F, Sironi L, Sirtori M, Tremoli E. Atherogenic lipoproteins and release of plasminogen activator inhibitor 1 (PAI-1) by endothelial cells. Fibrinolysis. 1990;4:79-81.
20. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Colien D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatoma cell line HepG2. Thromb Haemost. 1988;60:491-494.
21. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1354.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
23. Beisiegel U, Schneider WJ, Brown MS, Goldstein JL. Immunoblot analysis of low density lipoprotein receptors in fibroblasts from subjects with familial hypercholesterolemia. J Biol Chem. 1982;257:13150-13156.
24. Tremoli E, Camera M, Maderna P, Sironi L, Prati L, Colli S, Piovella F, Bernini F, Corsini A, Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs: an LDL receptor-independent phenomenon. Arterioscler Thromb. 1993;13:338-346.
25. Brown MS, Ho YK, Goldstein JL. The cholesteryl ester cycle in macrophage foam cells. J Biol Chem. 1980;255:9344-9352.
26. Chomezynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
27. Maniatis T, Fritsch EF, Sambrook J. Electrophoresis of RNA through gels containing formaldehyde. In: Molecular Cloning: A Laboratory Manual Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989:7.43-7.45.
28. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett. 1986;209:213-218.
29. Greenberg M, Ziff B. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature. 1984;311:433-438.
30. Colotta F, Polentarutti N, Sironi M, Mantovani A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem. 1992;267:18278-18283.
31. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-5299.
32. Emeis JJ, Kooistra T. Interleukin-1 and lipopolysaccharide induce a fast acting inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med. 1986;163:1260-1266.
33. Nelles L, Van Acker P, Collen D. Post-transcriptional effects of phorbol ester and cycloheximide on plasminogen activator inhibitor-1 mRNA levels in different human cell lines. Thromb Haemost. 1993;69:1098. Abstract.
34. Fattal PG, Schneider DJ, Sobel DJ, Billadello JJ. Post transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem. 1992;267:12412-12415.
35. Hopkins WE, Westerhausen DR Jr, Sobel BE, Billadello JJ. Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in HepG2 cells by epidermal growth factor. Nucleic Acids Res. 1991;19:163-168.
36. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. J Biol Chem. 1974;249:5153-5162.
37. Fielding PE, Vlodavsky I, Gospodarowicz D, Fielding CJ. Effect of contact inhibition on the regulation of cholesterol metabolism in cultured vascular endothelial cells. J Biol Chem. 1979;254:749-755.
38. Beisiegel U. Receptor for triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol. 1995;6:117-122.
39. 2+ and monoclonal antibodies, but not lipoproteins. J Biol Chem. 1987;262:17443-17449.
40. Beisiegel U, Weber W, Ihrke G, Hertz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 1989;341:162-164.
41. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA. 1992;89:9252-9256.
42. Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Danø K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator inhibitor from endothelial cells. J Clin Invest. 1986;78:1673-1680.
43. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human β-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA. 1986;83:6776-6780.
44. Loskutoff DJ, Linders M, Keijer J, Veerman H, van Heerikhuizen H, Pannekoek H. Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. Biochemistry. 1987;26:3763-3768.
45. Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. Human plasminogen activator inhibitor-1 gene. J Biol Chem. 1988;263:9129-9141.
46. Bosma PJ, Kooistra T. Different induction of two Plasminogen Activator Inhibitor 1 mRNA species by phorbol ester in human hepatoma cells. J Biol Chem. 1991;266:17845-17849.
47. Fattal PG, Billadello JJ. Species-specific differential cleavage and polyadenylation of plasminogen activator inhibitor type 1 hnRNA. Nucleic Acids Res. 1993;21:1463-1466.